Christina M. Ackermann
2021
Compensation breakdown
Non-Equity Incentive Plan | $862,000 |
---|---|
Option Awards | $600,033 |
Salary | $750,000 |
Stock Awards | $2,348,225 |
Other | $14,330 |
Total | $4,574,588 |
Ackermann received $2.3M in stock awards, accounting for 51% of the total pay in 2021.
Ackermann also received $862K in non-equity incentive plan, $600K in option awards, $750K in salary and $14.3K in other compensation.
Rankings
In 2021, Christina M. Ackermann's compensation ranked 2,890th out of 12,415 executives tracked by ExecPay. In other words, Ackermann earned more than 76.7% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 2,890 out of 12,415 | 77th |
Division Manufacturing | 1,150 out of 5,508 | 79th |
Major group Chemicals And Allied Products | 456 out of 2,378 | 81st |
Industry group Drugs | 400 out of 2,099 | 81st |
Industry Pharmaceutical Preparations | 268 out of 1,549 | 83rd |
Pay ratio
Christina M. Ackermann's Pay | $4,574,588 |
---|---|
Median Employee's Pay | $44,617 |
Pay Ratio | 103to 1 |
In 2021, the annual total compensation of Christina M. Ackermann was $4,574,588.
The annual total compensation of the median employee at Valeant Pharmaceuticals International was $44,617.
The ratio of Christina M. Ackermann's pay to the pay of median employee was therefore 103 to one.
Ackermann's colleagues
We found five more compensation records of executives who worked with Christina M. Ackermann at Valeant Pharmaceuticals International in 2021.
2021
Joseph Papa
Valeant Pharmaceuticals International
Chief Executive Officer
2021
Thomas Appio
Valeant Pharmaceuticals International
President Co, Head Bausch + Lomb/International
2021
Paul Herendeen
Valeant Pharmaceuticals International
Chief Financial Officer
2021
Sam Eldessouky
Valeant Pharmaceuticals International
Chief Financial Officer
2021
Robert Spurr
Valeant Pharmaceuticals International